|
Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM). |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Seagen |
|
|
Employment - Caris Life Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Vascular Biogenics |
Consulting or Advisory Role - NanoTX; Vascular Biogenics |
Research Funding - miRNA Therapeutics (Inst); Threshold Pharmaceuticals; Vascular Biogenics |
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics |
Travel, Accommodations, Expenses - Vascular Biogenics |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - Novocure (I) |
Honoraria - Cardinal Health; Gerson Lehrman Group |
Consulting or Advisory Role - Abbvie; Amgen; Cardinal Health; Merck; Novocure |
Speakers' Bureau - Bristol-Myers Squibb; Novocure; Prime Oncology |
Research Funding - Bristol-Myers Squibb (Inst); Novocure (Inst) |
Travel, Accommodations, Expenses - American Association of Neurological Surgeons; Bristol-Myers Squibb; Novocure; Xcenda |
|
|
Stock and Other Ownership Interests - Caris Life Sciences; Celldex |
Consulting or Advisory Role - Caris Life Sciences |
|
Patents, Royalties, Other Intellectual Property - Celldex |
Travel, Accommodations, Expenses - Caris Life Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |